[go: up one dir, main page]

AR059829A1 - Sistemas estables de nanocapsulas para la administracion de moleculas activas - Google Patents

Sistemas estables de nanocapsulas para la administracion de moleculas activas

Info

Publication number
AR059829A1
AR059829A1 ARP070101016A ARP070101016A AR059829A1 AR 059829 A1 AR059829 A1 AR 059829A1 AR P070101016 A ARP070101016 A AR P070101016A AR P070101016 A ARP070101016 A AR P070101016A AR 059829 A1 AR059829 A1 AR 059829A1
Authority
AR
Argentina
Prior art keywords
systems
nanocapsules
active molecules
administration
stable nanocapsules
Prior art date
Application number
ARP070101016A
Other languages
English (en)
Inventor
Luque Silvia Suarez
Fernandez Maria Jose Alonso
Pena Ana Isabel Vila
Original Assignee
Advanced In Vitro Cell Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced In Vitro Cell Tech filed Critical Advanced In Vitro Cell Tech
Publication of AR059829A1 publication Critical patent/AR059829A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dirige a sistemas nanocapsulares caracterizados por presentar una elevada estabilidad durante largos periodos de tiempo. Estos sistemas son utiles para la liberacion controlada de moléculas farmacologicamente o cosmetologicamente activas, especialmente de naturaleza fuertemente lipofílica. El sistema comprende nanocápsulas con un tamano medio inferior a 1 micrometro dispersas en un medio acuoso, donde las nanocápsulas tienen una estructura que comprende una fase lipofílica conteniendo un componente fosfolipídico y uno o más ácidos grasos de cadena C12-24 saturados y/o insaturados o derivados de los mismos; y una fase hidrofílica que comprende quitosano o un derivado del mismo y un compuesto polioxialquilenado. Composiciones farmacéuticas que comprenden dicho sistema y procedimiento de preparacion de dicho sistema.
ARP070101016A 2006-03-13 2007-03-13 Sistemas estables de nanocapsulas para la administracion de moleculas activas AR059829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06380048A EP1834635B1 (en) 2006-03-13 2006-03-13 Stable nanocapsule systems for the administration of active molecules

Publications (1)

Publication Number Publication Date
AR059829A1 true AR059829A1 (es) 2008-04-30

Family

ID=36743270

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101016A AR059829A1 (es) 2006-03-13 2007-03-13 Sistemas estables de nanocapsulas para la administracion de moleculas activas

Country Status (17)

Country Link
US (1) US20090074824A1 (es)
EP (1) EP1834635B1 (es)
JP (1) JP5222739B2 (es)
KR (1) KR20080102303A (es)
CN (1) CN101426479B (es)
AR (1) AR059829A1 (es)
AT (1) ATE515260T1 (es)
AU (1) AU2007224471B2 (es)
BR (1) BRPI0709594A2 (es)
CA (1) CA2646338A1 (es)
DK (1) DK1834635T3 (es)
ES (1) ES2369244T3 (es)
IL (1) IL194005A0 (es)
PE (1) PE20080141A1 (es)
PL (1) PL1834635T3 (es)
PT (1) PT1834635E (es)
WO (1) WO2007104732A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119780B2 (en) 2006-06-02 2012-02-21 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
US20080248508A1 (en) * 2006-08-17 2008-10-09 Shenda Baker Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials
US20100203163A1 (en) * 2007-06-12 2010-08-12 Christine Allen Injectable polymer-lipid blend for localized drug delivery
EP2042166A1 (en) * 2007-09-25 2009-04-01 The Jordanian Pharmaceutical Manufacturing Co. Nanocapsules for oral delivery of proteins
SI2200588T1 (sl) * 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
KR101199580B1 (ko) * 2008-08-06 2013-11-27 (주)에델프라우 국소 투여용 나노에멀젼
BRPI0805854A2 (pt) 2008-10-10 2010-08-24 Biolab Sanus Farmaceutica Ltda sistema nanoparticulado, processo de preparaÇço do mesmo, uso do mesmo, composiÇço fotoproterora, processo de preparaÇço da mesma, mÉtodo de prevenÇço de doenÇas e distérbios da pele
TWI328565B (en) * 2008-12-19 2010-08-11 Taiwan Textile Res Inst Dispersions of conductive carbon materials and methods for preparing the same
CA2755068C (en) 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
EP2266546A1 (en) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2364600A1 (en) * 2010-02-18 2011-09-14 Nestec S.A. Liquid-filled chitosan-anionic liposoluble capsule dispsersions
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
KR20130028967A (ko) * 2010-06-23 2013-03-20 브라잇사이드 이노베이션스 인크. 레시틴 캐리어 베시클 및 이의 제조 방법
US20140005269A1 (en) * 2010-11-26 2014-01-02 University Of The Witwatersrand, Johannesburg Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form
US9801829B2 (en) * 2011-04-29 2017-10-31 University Of Florida Research Foundation, Inc. Methods and systems of making nanostructures
DE102011076149A1 (de) * 2011-05-19 2012-11-22 Rovi Cosmetics International Gmbh Ladungsgeber für ein vesikuläres Trägersystem eines UV-Schutzmittels für die Haut oder die Haare
ES2366255B2 (es) * 2011-06-27 2012-08-08 Universidade De Santiago De Compostela Nanocomposiciones sacarídicas para la liberación de vacunas.
MX351092B (es) 2011-11-02 2017-10-02 Keybioscience Ag Analogos peptidicos para tratar enfermedades y trastornos.
DK3095484T3 (en) 2011-11-02 2018-06-25 Keybioscience Ag CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
WO2013074616A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
US8968790B2 (en) * 2011-12-09 2015-03-03 Shaker A. Mousa Nanoformulation of vitamin D derivatives and/or vitamin D metabolites
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
WO2014096165A2 (en) * 2012-12-21 2014-06-26 Bracco Suisse Sa Gas-filled microvesicles
PL3057604T3 (pl) 2013-10-14 2021-12-20 Nanosphere Health Sciences Inc. Kompozycje nanocząstek i sposoby jako nośniki czynników nutraceutycznych przez błony komórkowe i bariery biologiczne
EP3068796B1 (en) 2013-11-14 2018-01-31 KeyBioscience AG Calcitonin mimetics for treating diseases and disorders
CN104117066B (zh) * 2014-07-16 2016-03-02 陈凌 外敷用抗甲状腺软膏的制备方法
CA2970917C (en) * 2014-12-15 2019-09-17 Nanosphere Health Sciences, Llc Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
EP3268043A4 (en) 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
PL229276B1 (pl) * 2015-07-17 2018-06-29 Univ Jagiellonski Nanokapsuła do przenoszenia związku lipofilowego i sposób jej wytwarzania
TWI709410B (zh) * 2015-08-11 2020-11-11 荷蘭商艾西優藥物股份有限公司 具有生物活性親脂性化合物之聚乙二醇化脂質奈米粒子
KR20180128025A (ko) * 2016-03-25 2018-11-30 아디쎄오 프랑스 에스에이에스 지용성 활성 성분을 포함하는 나노캡슐, 그 제조 방법 및 그 용도
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
WO2020123407A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
KR102384808B1 (ko) * 2018-12-20 2022-04-08 주식회사 스킨메드 키토산으로 코팅된 나노 캡슐 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
EP0570829B1 (de) * 1992-05-18 2001-04-25 CicloMulsion AG Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
US20030224022A1 (en) * 1993-01-19 2003-12-04 Amos Nussinovitch Hydrocolloid cellular solid matrices
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
JP3441665B2 (ja) * 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
EP1190702A1 (en) * 2000-09-22 2002-03-27 Ciba SC Holding AG Chitosan emulsion formulation
ATE286430T1 (de) * 2001-03-22 2005-01-15 Cognis Iberia Sl Nanokapseln
CN100335036C (zh) * 2001-11-01 2007-09-05 耶路撒冷希伯来语大学依苏姆研究开发公司 用于干眼症治疗的方法和组合物

Also Published As

Publication number Publication date
EP1834635B1 (en) 2011-07-06
JP2009530241A (ja) 2009-08-27
KR20080102303A (ko) 2008-11-24
ES2369244T3 (es) 2011-11-28
CA2646338A1 (en) 2007-09-20
EP1834635A1 (en) 2007-09-19
PE20080141A1 (es) 2008-03-04
IL194005A0 (en) 2011-08-01
DK1834635T3 (da) 2011-10-24
WO2007104732A3 (en) 2007-11-08
BRPI0709594A2 (pt) 2011-07-19
WO2007104732A2 (en) 2007-09-20
PL1834635T3 (pl) 2012-01-31
AU2007224471A1 (en) 2007-09-20
AU2007224471B2 (en) 2013-05-02
US20090074824A1 (en) 2009-03-19
ATE515260T1 (de) 2011-07-15
CN101426479A (zh) 2009-05-06
JP5222739B2 (ja) 2013-06-26
PT1834635E (pt) 2011-10-13
CN101426479B (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
AR059829A1 (es) Sistemas estables de nanocapsulas para la administracion de moleculas activas
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
CO6220926A2 (es) Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid)
AR081535A1 (es) Formulaciones liquidas oleosas estables listas para usar, su preparacion y uso
EA201490921A1 (ru) Устойчивые составы с контролируемым высвобождением
BR112016018673A2 (pt) Composições de sistemas de distribuição de nanoemulsão
CL2011000244A1 (es) Formulacion farmaceutica intra-arterial que comprende particulas esfericas que contienen un factor de crecimiento y un excipiente biodegradable, en donde el diametro medio de dichas particulas es de 15-20 micrometros, con una desviacion estandar de (+/-) 1 micrometro en al menos 99% de las particulas; y su uso en el tratamiento de infarto al miocardio, trastorno cardiaco isquemico, entre otros.
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
EA201270050A1 (ru) Нанодисперсия лекарственного средства и способ ее получения
PH12014500449B1 (en) Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
NZ596657A (en) Self micro-emulsifying oral pharmaceutical composition of hydrophilic drug and preparation method thereof
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
AR056808A1 (es) Formulacion de aceite en agua de avermectinas
CL2011001225A1 (es) Formulacion farmaceutica en solucion acuosa que comprende desde 1% hasta 5% (p/v) de una sal de diclofenaco, desde 3% hasta 30% (p/v) de al menos un polioxialquilen ester de hidroxido de acido graso y un co-solvente seleccionado de etanol, propanol, glicerol, propilenglicol entre otros.
AR077338A1 (es) Formulacion farmaceutica. procedimiento de preparacion. disolucion para perfusion.
AR053737A1 (es) Formulacion pediatrica de topiramato
NZ610465A (en) Clevidipine emulsion formulations containing antimicrobial agents
ES2720954T3 (es) Formulaciones estabilizadas de estatina
AR072223A1 (es) Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en el ganado vacuno
MX2019003698A (es) Composicion que comprende al menos una sal farmaceuticamente aceptable de elafibranor soluble en medio acuoso que muestra una absorcion intestinal mejorada.
AR092840A1 (es) Elaboracion de degarelix
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
NO20084478L (no) Konjugerte lipidderivater

Legal Events

Date Code Title Description
FB Suspension of granting procedure